Home › Germ Cell and Embryonal Cancer › Missouri › St. Louis
Germ Cell and Embryonal Cancer clinical trials in St. Louis, MO
4 studies for Germ Cell and Embryonal Cancer are looking for participants at sites in and around St. Louis (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
RecruitingPhase 1
- Siteman Cancer Center at Washington University, St Louis
Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
RecruitingPhase 3
- Washington University School of Medicine, St Louis
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
RecruitingPhase 3
- Washington University School of Medicine, St Louis
- Missouri Baptist Medical Center, St Louis
- Mercy Hospital Saint Louis, St Louis
- and 1 more
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
RecruitingPhase 1/2
- Washington University Infusion Center Pharmacy, St Louis
Germ Cell and Embryonal Cancer trials in other cities
- Houston, TX6 studies
- Columbus, OH5 studies
- New York City, NY5 studies
- Chicago, IL4 studies
- Indianapolis, IN4 studies
- Memphis, TN3 studies
- Dallas, TX3 studies
- Boston, MA3 studies
- Winston-Salem, NC3 studies
- Greenburgh, NY3 studies
- Clifton, NJ3 studies
- San Francisco, CA3 studies
Other studies in St. Louis
- Non-Small Cell Lung Cancer73 studies
- Breast Cancer64 studies
- Metastatic Cancer54 studies
- Colorectal Cancer50 studies
- Cancer (all types)46 studies
- Prostate Cancer46 studies
- Lung Cancer39 studies
- Ovarian Cancer38 studies
- Pancreatic Cancer33 studies
- Endometrial Cancer29 studies
- Head and Neck Squamous Cell Carcinoma28 studies
- Heart Failure26 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.